Key facts
- Notable investors include Unpopular Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Delineate (Healthcare Technology Systems)
- ·The full record, as it builds
Funding rounds
No funding rounds for Delineate (Healthcare Technology Systems) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Delineate (Healthcare Technology Systems)
Developer of a co-pilot quantitative pharmacology system designed to help scientists enhance computational modeling in drug development. The company's AI-powered platform leverages large language model capabilities to streamline literature workflows, enabling clients with multi-source parameter extraction, table and equation extraction, plot digitization, biological mechanism exploration, model replication, and comprehensive drug development optimization.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2024
- Employees
- 22
- Website
- delineate.pro/
- Ownership
- Privately Held (backing)
Delineate (Healthcare Technology Systems) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Delineate (Healthcare Technology Systems) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Delineate (Healthcare Technology Systems) in its N-PORT filings yet. We sweep new filings monthly.